Hospira's Precedex "provides comparable effectiveness"
3 February 2009 00:00 in Pharmacy Supplier News
Hospira's Precedex "provides comparable effectiveness", according to a phase IV study.
The research - published in the Journal of the American Medical Association - revealed the product also allowed patients to be removed from mechanical ventilation two days earlier when treated with the drug.
According to the article the study appears in, the incidence of delirium during treatment of subjects on Precedex was 54 per cent, compared to 76.6 per cent in people given midazolam therapies.
Commenting on the results, Richard Riker, director of critical care research for the Division Pulmonary and Critical Care Medicine at Maine Medical Centre in the US, said the study was "one of the largest" to compare two different sedatives for use in intensive care units.
He added: "I expect that patients requiring long-term sedation, their families and healthcare providers will welcome the results of this trial."
Last year, the company announced a new indication for Precedex has received approval in the US.
Other news stories from 03/02/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency